chronic renal failure
DESCRIPTION
CHRONIC RENAL FAILURE. JAKUB ZÁVADA KLINIKA NEFROLOGIE 1.LF UK. DEFINITION. PROGRESSIVE AND IRREVERSIBLE LOSS OF RENAL FUNCTION K/DOQI CLASSIFICATION: 1. NORMAL/INCREASED GFR BUT SOME EVIDENCE OF RENAL DISEASE (microalbuminuria/proteinuria, hematuria, histological changes) - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/1.jpg)
CHRONIC RENAL FAILURE
JAKUB ZÁVADA
KLINIKA NEFROLOGIE 1.LF UK
![Page 2: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/2.jpg)
DEFINITION
• PROGRESSIVE AND IRREVERSIBLE LOSS OF RENAL FUNCTION
• K/DOQI CLASSIFICATION:1. NORMAL/INCREASED GFR BUT SOME EVIDENCE OF RENAL
DISEASE
(microalbuminuria/proteinuria, hematuria, histological changes)
2. MILD DECREASE OF GFR
(60-89 ml/min/1,73m2 = 1-1,49 ml/s/1,73m2)
3. MODERATE DECREASE OF GFR
(30-59 ml/min/1,73m2 = 0,5-0,99 ml/s/1,73m2)
4. SEVERE DECREASE OF GFR
(15-30 ml/min/1,73m2 = 0,25-0,49 ml/s/1,73m2)
5. KIDNEY FAILURE, RRT TO BE CONSIDERED
(GFR < 15 ml/min/1,73m2 = 0,25ml/s/1,73m2)
![Page 3: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/3.jpg)
![Page 4: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/4.jpg)
![Page 5: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/5.jpg)
EPIDEMIOLOGY
• INCIDENCE OF ESRD: 110 (UK)- 315 (USA) PTS/1000000/YEAR (IN 1999)
• PREVALENCE OF ESRD: 659 (EU) – 1217 (USA) PTS/1000000/YEAR (IN 1999)
• INCIDENCE OF ESRD IS RISING AT A RATE OF 6-7% PER YEAR
• MOST COMMON ETIOLOGY: DM, HYPERTENSION, CHRONIC GLOMERULONEPHRITIS
ESRD=END STAGE RENAL DISEASERRT=RENAL REPLACEMENT THERAPYCRF=CHRONIC RENAL FAILUREGFR=GLOMERULAR FILTRATION RATE
![Page 6: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/6.jpg)
![Page 7: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/7.jpg)
FACTORS AFFECTING PROGRESSION OF CRF
• NONMODIFIABLE RISK FACTORS:– UNDERLYING NEPHROPATHY– AGE, GENDER, RACE, GENES
• MODIFIABLE RISK FACTORS:– PROTEINURIA– HYPERTENSION– GLYCEMIA– LIPIDS– OBESITY– HYPERURICEMIA– SMOKING
![Page 8: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/8.jpg)
![Page 9: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/9.jpg)
![Page 10: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/10.jpg)
![Page 11: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/11.jpg)
MECHANISMS OF PROGRESSION OF CRF
• GLOMERULOSCLEROSIS– ENDOTHELIAL INJURY → MESANGIAL
PROLIFERATION → GLOMERULAR SCLEROSIS
• TUBULOINTERSTICIAL SCARRING– TUBULAR CELL INJURY → RELEASE OF
INFLAMMATORY MEDIATORS → STIMULATION OF RENAL FIBROBLASTS → FIBROSIS
• VASCULAR SCLEROSIS– ARTERIOLAR HYALINOSIS, LOSS OF
PERITUBULAR CAPILLARIES → INTERSTITICIAL ISCHEMIA → INTERSTICIAL FIBROSIS
![Page 12: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/12.jpg)
![Page 13: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/13.jpg)
![Page 14: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/14.jpg)
CLINICAL PRESENTATION OF CRF
• CHRONIC KIDNEY DISEASE (K/DOQI STAGES 2-4)
• ACUTE-ON-CHRONIC RENAL FAILURE
• LATE REFERRAL OF CRF, UREMIC EMERGENCY
![Page 15: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/15.jpg)
COMPLICATIONS AND CONSEQUENCES OF CRF
• CARDIOVASCULAR DISEASE• ANEMIA• RENAL BONE DISEASE• METABOLIC ACIDOSIS• MALNUTRITION• HYPERVOLEMIA• HYPERKALEMIA• BLEEDING DIATHESIS• DERMATOLOGIC MANIFESTATIONS• NEUROLOGIC MANIFESTATIONS• IMMUNOSUPRESSION
![Page 16: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/16.jpg)
MANAGEMENT OF CRF
• DEFINE THE CAUSE• LOOK FOR REVERSIBILITY
– PRE-RENAL, DRUG TOXICITY, IMMUNE-MEDIATED, INFECTION, OBSTRUCTION, HYPERCALCEMIA, HYPERTENSION
• MINIMIZE PROGRESSION OF CRF• PREVENT AND TREAT COMPLICATIONS OF CRF• PREPARE FOR RENAL REPLACEMENT THERAPY• DRUGS
– ADJUST DOSE: ANTIMICROBIAL DRUGS, DIGOXIN, LITHIUM, CARBAMAZEPINE
– AVOID: METFORMIN, NSAID, CYCLOSPORINE, MAGNESIUM
![Page 17: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/17.jpg)
![Page 18: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/18.jpg)
DIETARY INTERVENTIONS IN CRF
– LOW PROTEIN DIET (?) MDRD STUDY FAILED TO SHOW BENEFIT
– LOW-PHOSPHATE DIET (HELPS TO CONTROL HYPERPHOSPHATEMIA AND RENAL OSTEODYSTROPHY)
– SUPPLEMENTAION OF FISH OILS (?) PERHAPS HELPFUL IN IGA NEPHROPATHY (CONTROVERSIAL)
– SALT RESTRICTION (HELPS TO CONTROL HYPERTENSION AND VOLUME OVERLOAD)
![Page 19: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/19.jpg)
PHARMACOLOGICAL INTERVENTIONS IN CRF
BLOOD PRESSURE CONTROL– BP GOAL:
• GENERAL POPULATION 140/90• CKD STAGE 1-4 + PROTEINURIA<1G/DAY 135/85• CKD STAGE 1-4 + PROTEINURIA>1G/DAY 125/75
– ANTIHYPERTENSIVE AGENTS1) ACEI (ACE INHIBITORS)
2) + DIURETIC + LOW SALT DIET3) + ATRA (ANGIOTENSIN RECEPTOR ANTAGONISTS)
4) + NDCCB (NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS)
CAVE: ACEI and ATRA are renoprotective via reduction of intraglomerular pressure, which could lead to mild decrease in GFR and mild increase in s-creatinin (not a reason to avoid them!).
In older patients and patients with renovascular disease these drugs could lead to severe deterioration of renal function (close monitoring needed, if this happens, avoid them)
ACEi and ATRA could cause hyperkalemia (close monitoring needed)
![Page 20: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/20.jpg)
![Page 21: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/21.jpg)
![Page 22: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/22.jpg)
SUPPORTIVE CARE AND PREPARATION OF RENAL REPLACEMENT THERAPY
• SALT, POTASSIUM AND WATER BALANCE– LOW SODIUM, LOW POTTASIUM DIET, DIURETICS
• SECONDARY HYPERPARATHYROIDISM AND BONE DISEASE– LOW PHOSPHATE DIET, ORAL PHOSPHATE BINDERS
– VITAMIN D SUPPLEMENTATION
• ANEMIA– ERYTHROPOETIN
• HBV VACCINATION• CHOICE OF RRT
– HEMODIALYSIS, PERITONEAL DAILYSIS, PRE-EMPTIVE TRANSPLANTATION
• DIALYSIS ACCESS• TIMING OF STARTING DIALYSIS TREATMENT
![Page 23: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/23.jpg)
![Page 24: CHRONIC RENAL FAILURE](https://reader031.vdocument.in/reader031/viewer/2022020111/568153ef550346895dc1f0fd/html5/thumbnails/24.jpg)